Critical Outcome Technologies Inc. - Product Pipeline Review - 2016

  • ID: 3961134
  • Company Profile
  • 43 pages
  • Global Markets Direct
1 of 4
Critical Outcome Technologies Inc. - Product Pipeline Review - 2016

‘Critical Outcome Technologies Inc. - Product Pipeline Review - 2016’, provides an overview of the Critical Outcome Technologies Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Critical Outcome Technologies Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

- The report provides a snapshot of the pipeline therapeutic landscape of Critical Outcome Technologies Inc.
- The report provides overview of Critical Outcome Technologies Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Critical Outcome Technologies Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Critical Outcome Technologies Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy:

- Evaluate Critical Outcome Technologies Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Critical Outcome Technologies Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Critical Outcome Technologies Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Critical Outcome Technologies Inc. Snapshot

Critical Outcome Technologies Inc. Overview

Key Facts

Critical Outcome Technologies Inc. - Research and Development Overview

Key Therapeutic Areas

Critical Outcome Technologies Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Critical Outcome Technologies Inc. - Pipeline Products Glance

Critical Outcome Technologies Inc. - Clinical Stage Pipeline Products

Phase I Products/Combination Treatment Modalities

Critical Outcome Technologies Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Critical Outcome Technologies Inc. - Drug Profiles

COTI-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COTI-219 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COTI-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COTI-58 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for MRSA Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Acute Myelocytic Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Small Cell Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize VEGF-R and PDGF-R for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Angiogenesis for Undisclosed Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDKs for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Microtubulin for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Thymidylate Synthase and THFR for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Critical Outcome Technologies Inc. - Pipeline Analysis

Critical Outcome Technologies Inc. - Pipeline Products by Target

Critical Outcome Technologies Inc. - Pipeline Products by Route of Administration

Critical Outcome Technologies Inc. - Pipeline Products by Molecule Type

Critical Outcome Technologies Inc. - Pipeline Products by Mechanism of Action

Critical Outcome Technologies Inc. - Dormant Projects

Critical Outcome Technologies Inc. - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Critical Outcome Technologies Inc., Key Facts

Critical Outcome Technologies Inc. - Pipeline by Indication, 2016

Critical Outcome Technologies Inc. - Pipeline by Stage of Development, 2016

Critical Outcome Technologies Inc. - Monotherapy Products in Pipeline, 2016

Critical Outcome Technologies Inc. - Phase I, 2016

Critical Outcome Technologies Inc. - Preclinical, 2016

Critical Outcome Technologies Inc. - Discovery, 2016

Critical Outcome Technologies Inc. - Pipeline by Target, 2016

Critical Outcome Technologies Inc. - Pipeline by Route of Administration, 2016

Critical Outcome Technologies Inc. - Pipeline by Molecule Type, 2016

Critical Outcome Technologies Inc. - Pipeline Products by Mechanism of Action, 2016

Critical Outcome Technologies Inc. - Dormant Developmental Projects,2016

List of Figures

Critical Outcome Technologies Inc. - Pipeline by Top 10 Indication, 2016

Critical Outcome Technologies Inc. - Pipeline by Stage of Development, 2016

Critical Outcome Technologies Inc. - Monotherapy Products in Pipeline, 2016

Critical Outcome Technologies Inc. - Pipeline by Top 10 Target, 2016

Critical Outcome Technologies Inc. - Pipeline by Route of Administration, 2016

Critical Outcome Technologies Inc. - Pipeline by Molecule Type, 2016

Critical Outcome Technologies Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll